

**Contact**

Merck KGaA, Darmstadt, Germany

Investor Relations

Frankfurter Strasse 250

64293 Darmstadt

Germany

Phone: +49 6151 72 3321

e-mail: [investor.relations@emdgroup.com](mailto:investor.relations@emdgroup.com)

[www.emdgroup.com](http://www.emdgroup.com)

WKN: 659990

ISIN: DE0006599905

Ticker Symbol: MRK

## Financial Statements Q1 2019 – Q2 2020

**Content**

---

**1 Income statements**

- 1.1 Group, quarterly
- 1.2 Healthcare, quarterly
- 1.3 Life Science, quarterly
- 1.4 Performance Materials, quarterly
- 1.5 Corporate/Others, quarterly

**2 Cash flow statement****3 Balance sheet**

**EBITDA pre Merck KGaA, Darmstadt, Germany**

€ million	2019								2020							Change YoY												
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY				
Healthcare	332.0	527.8	859.8	500.8	1,360.6	561.1	1,061.9	1,921.7	472.1	374.0	846.2								42.2%	-29.1%	-1.6%							
<i>in % of net sales</i>	22.4%	31.5%	27.2%	28.5%	27.7%	31.2%	29.9%	28.6%	27.8%	24.9%	26.4%																	
Life Science	515.7	533.3	1,049.0	531.1	1,580.1	548.7	1,079.8	2,128.9	552.7	569.0	1,121.8								7.2%	6.7%	6.9%							
<i>in % of net sales</i>	31.0%	31.3%	31.2%	31.0%	31.1%	30.8%	30.9%	31.0%	31.2%	31.5%	31.4%																	
Performance Materials	192.6	190.3	382.9	177.5	560.4	243.0	420.5	803.4	285.5	238.3	523.8								48.3%	25.2%	36.8%							
<i>in % of net sales</i>	31.9%	32.3%	32.1%	30.5%	31.6%	30.5%	30.5%	31.2%	31.7%	29.3%	30.6%																	
Corporate/Others	-111.8	-112.1	-223.9	-98.1	-322.0	-147.2	-245.3	-469.2	-129.1	-107.2	-236.2								15.5%	-4.5%	5.5%							
<b>Group</b>	<b>928.5</b>	<b>1,139.3</b>	<b>2,067.8</b>	<b>1,111.3</b>	<b>3,179.1</b>	<b>1,205.7</b>	<b>2,316.9</b>	<b>4,384.8</b>	<b>1,181.3</b>	<b>1,074.2</b>	<b>2,255.5</b>								27.2%	-5.7%	9.1%							
<i>in % of net sales</i>	24.8%	28.7%	26.8%	27.4%	27.0%	27.5%	27.5%	27.1%	27.0%	26.1%	26.6%																	

Sum of items may not foot due to rounding.

**Income Statement Merck KGaA, Darmstadt, Germany**

Group € million	2019									2020									Change YoY									
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY				
<b>Net sales</b>	<b>3,745.8</b>	<b>3,971.4</b>	<b>7,717.2</b>	<b>4,053.7</b>	<b>11,770.9</b>	<b>4,380.8</b>	<b>8,434.5</b>	<b>16,151.7</b>	<b>4,369.7</b>	<b>4,119.1</b>	<b>8,488.8</b>																	
Cost of sales	-1,383.5	-1,454.4	-2,838.0	-1,477.9	-4,315.9	-1,690.4	-3,168.3	-6,006.3	-1,653.5	-1,610.3	-3,263.9							16.7%	3.7%	10.0%								
thereof amortization of intangible assets	-43.5	-43.7	-87.2	-44.0	-131.2	-56.9	-100.9	-188.1	-56.7	-57.2	-113.9							19.5%	10.7%	15.0%								
Gross profit	2,362.2	2,517.0	4,879.2	2,575.8	7,455.1	2,690.4	5,266.2	10,145.5	2,716.2	2,508.7	5,224.9							15.0%	-0.3%	7.1%								
<i>in % of net sales</i>	63.1%	63.4%	63.2%	63.5%	63.3%	61.4%	62.4%	62.8%	62.2%	60.9%	61.6%																	
SG&A	-1,456.8	-1,345.3	-2,802.1	-1,409.5	-4,211.6	-1,545.6	-2,955.2	-5,757.3	-1,421.0	-1,497.5	-2,918.6							-2.5%	11.3%	4.2%								
<i>in % of net sales</i>	38.9%	33.9%	36.3%	34.8%	35.8%	35.3%	35.0%	35.6%	32.5%	36.4%	34.4%																	
Marketing and selling expenses	-1,090.8	-1,156.9	-2,247.6	-1,100.4	-3,348.1	-1,228.4	-2,328.8	-4,576.5	-1,058.7	-1,034.9	-2,093.6							-2.9%	-10.5%	-6.9%								
thereof amortization of intangible assets (M&S)	-222.6	-225.0	-447.6	-217.6	-665.2	-257.4	-475.0	-922.6	-158.8	-165.2	-323.9							-28.7%	-26.6%	-27.6%								
Administration expenses	-283.0	-269.1	-552.1	-267.5	-819.6	-334.3	-601.8	-1,153.9	-288.5	-298.3	-586.8							1.9%	10.8%	6.3%								
Impairment losses and reversals (IFRS 9)	-3.9	2.2	-1.8	-1.2	-3.0	-4.6	-5.8	-7.5	6.0	-4.5	1.5							n.m.	n.m.	n.m.								
Other operating expenses/income	-79.1	78.5	-0.6	-40.4	-40.9	21.6	-18.8	-19.3	-79.8	-159.9	-239.6							0.9%	n.m.	>1.000%								
Impairments**	0.0	0.0	0.0	-8.4	-8.4	-0.7	-9.1	-9.1	-1.9	-111.7	-113.6							>1.000%	n.m.	>1.000%								
Research and development	-526.6	-553.2	-1,079.9	-558.3	-1,638.1	-630.1	-1,188.4	-2,268.2	-579.2	-520.0	-1,099.2							10.0%	-6.0%	1.8%								
<i>in % of net sales</i>	14.1%	13.9%	14.0%	13.8%	13.9%	14.4%	14.1%	14.0%	13.3%	12.6%	12.9%																	
thereof amortization of intangible assets (R&D)	-1.0	-0.7	-1.6	-1.9	-3.5	-5.1	-7.0	-8.6	-2.3	-2.8	-5.1							144.0%	327.7%	219.2%								
<b>EBIT</b>	<b>378.8</b>	<b>618.4</b>	<b>997.3</b>	<b>608.0</b>	<b>1,605.3</b>	<b>514.6</b>	<b>1,122.7</b>	<b>2,120.0</b>	<b>715.9</b>	<b>491.2</b>	<b>1,207.1</b>							89.0%	-20.6%	21.0%								
<i>in % of net sales</i>	10.1%	15.6%	12.9%	15.0%	13.6%	11.7%	13.3%	13.1%	16.4%	11.9%	14.2%																	
Depreciation and amortization	474.0	455.4	929.4	464.3	1,393.7	552.6	1,016.9	1,946.3	431.5	556.4	987.9							-9.0%	22.2%	6.3%								
<b>EBITDA</b>	<b>852.8</b>	<b>1,073.9</b>	<b>1,926.7</b>	<b>1,072.3</b>	<b>2,999.0</b>	<b>1,067.3</b>	<b>2,139.6</b>	<b>4,066.3</b>	<b>1,147.5</b>	<b>1,047.5</b>	<b>2,195.1</b>							34.6%	-2.5%	13.9%								
<i>in % of net sales</i>	22.8%	27.0%	25.0%	26.5%	25.5%	24.4%	25.4%	25.2%	26.3%	25.4%	25.9%																	
<b>EBITDA pre</b>	<b>928.5</b>	<b>1,139.3</b>	<b>2,067.8</b>	<b>1,111.3</b>	<b>3,179.1</b>	<b>1,205.7</b>	<b>2,316.9</b>	<b>4,384.8</b>	<b>1,181.3</b>	<b>1,074.2</b>	<b>2,255.5</b>							27.2%	-5.7%	9.1%								
<i>in % of net sales</i>	24.8%	28.7%	26.8%	27.4%	27.0%	27.5%	27.5%	27.1%	27.0%	26.1%	26.6%																	
Financial result	-112.6	-61.1	-173.7	-134.9	-308.5	-76.1	-210.9	-384.6	-98.5	-102.3	-200.7							-12.5%	67.4%	15.6%								
Profit before income tax from continuing operations	266.2	557.4	823.6	473.2	1,296.8	438.6	911.8	1,735.4	617.5	388.9	1,006.4							131.9%	-30.2%	22.2%								
Income tax	-67.2	-136.2	-203.4	-133.7	-337.1	-102.6	-236.4	-439.8	-159.4	-99.9	-259.4							137.4%	-26.7%	27.5%								
<i>Income tax rate</i>	25.2%	24.4%	24.7%	28.3%	26.0%	23.4%	25.9%	25.3%	25.8%	25.7%	25.8%																	
Profit after tax from continuing operations	199.1	421.1	620.2	339.5	959.7	335.9	675.4	1,295.6	458.0	289.0	747.0							130.1%	-31.4%	20.4%								
Profit after tax from discontinued operations	-9.6	49.7	40.2	2.4	42.6	-14.7	-12.2	27.9	0.0	0.0	0.0							-100.0%	-100.0%	-100.0%								
Profit after tax	189.5	470.9	660.4	341.9	1,002.3	321.3	663.2	1,323.6	458.0	289.0	747.0							141.7%	-38.6%	13.1%								
<b>of which: attributable to Merck KGaA shareholders (n of which: attributable to non-controlling interests)</b>	<b>188.6</b> <b>1.0</b>	<b>470.9</b> <b>0.0</b>	<b>659.5</b> <b>1.0</b>	<b>342.7</b> <b>-0.8</b>	<b>1,002.2</b> <b>0.1</b>	<b>318.1</b> <b>3.2</b>	<b>660.8</b> <b>2.4</b>	<b>1,320.2</b> <b>3.3</b>	<b>456.1</b> <b>1.9</b>	<b>289.8</b> <b>-0.8</b>	<b>745.9</b> <b>1.1</b>							141.9%	-38.5%	13.1%								
<b>EPS in €</b>	<b>0.43</b>	<b>1.08</b>	<b>1.52</b>	<b>0.79</b>	<b>2.31</b>	<b>0.73</b>	<b>1.52</b>	<b>3.04</b>	<b>1.05</b>	<b>0.67</b>	<b>1.72</b>							144.2%	-38.0%	13.2%								
thereof from continuing operations	0.45	0.97	1.42	0.78	2.20	0.77	1.55	2.97	1.05	0.67	1.72							133.3%	-30.9%	21.1%								
thereof from discontinued operations	-0.02	0.11	0.09	0.01	0.10	-0.03	-0.02	0.07	0.00	0.00	0.00							-100.0%	-100.0%	-100.0%								
<b>EPS pre in €*</b>	<b>1.13</b>	<b>1.54</b>	<b>2.67</b>	<b>1.35</b>	<b>4.02</b>	<b>1.54</b>	<b>2.89</b>	<b>5.56</b>	<b>1.50</b>	<b>1.30</b>	<b>2.80</b>							32.7%	-15.6%	4.9%								
<b>Number of theoretical shares in million</b>	<b>434.8</b>	<b>434.8</b>	<b>434.8</b>	<b>434.8</b>	<b>434.8</b>	<b>434.8</b>	<b>434.8</b>	<b>434.8</b>	<b>434.8</b>	<b>434.8</b>	<b>434.8</b>																	
<b>Reconciliation to EBITDA pre</b>																												
EBITDA	852.8	1,073.9	1,926.7	1,072.3	2,999.0	1,067.3	2,139.6	4,066.3	1,147.5	1,047.5	2,195.1							34.5%	-2.5%	13.9%								
<b>Adjustments</b>																												
thereof: Cost of Sales	16.0	3.4	19.4	7.3	26.7	29.4	36.7	56.1	20.2	2.5	22.7							26.5%	-27.1%	17.0%								
thereof: Marketing and selling expenses	3.0	4.8	7.8	1.9	9.7	0.6	2.5	10.3	2.2	10.3	12.5							-26.2%	114.9%	60.8%								
thereof: Administration expenses	36.7	10.6	47.4	21.9	69.3	39.8	61.7	109.0	16.4	32.8	49.2							-55.3%	207.7%	3.8%								
thereof: Other operating expenses/income	4.3	29.5	33.8	17.6	51.4	62.8	80.4	114.2	-3.7	-18.6	-22.3							n.m.	n.m.	n.m.								
thereof: Research and development	15.7	17.1	32.8	-9.7	23.1	5.8	-3.9	28.9	-1.2	-0.3	-1.6							n.m.	n.m.	n.m.								
<b>Total</b>	<b>75.7</b>	<b>65.4</b>	<b>141.1</b>	<b>39.0</b>	<b>180.1</b>	<b>138.4</b>	<b>177.3</b>	<b>318.5</b>	<b>33.8</b>	<b>26.7</b>	<b>60.5</b>							-55.3%	-59.2%	-57.1%								
<b>EBITDA pre</b>	<b>928.5</b>	<b>1,139.3</b>	<b>2,067.8</b>	<b>1,111.3</b>	<b>3,179.1</b>	<b>1,205.7</b>	<b>2,316.9</b>	<b>4,384.8</b>	<b>1,181.3</b>	<b>1,074.2</b>	<b>2,255.5</b>							27.2%	-5.7%	9.1%								

Sum of items may not foot due to rounding.

\* for continuing operations

\*\* only reflects impairments which classified as adjustments

**Reconciliation to EBITDA, EBITDA pre and EPS pre**

Group € million	2019								2020								Change YoY											
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY				
<b>a) Reconciliation to EBITDA and EBITDA pre</b>																												
<b>EBITDA</b>																												
EBIT	378.8	618.4	997.3	608.0	1,605.3	514.6	1,122.7	2,120.0	715.9	491.2	1,207.1															89.0%	-20.6%	21.0%
Depreciation and amortization	474.0	455.4	929.4	464.3	1,393.7	552.6	1,016.9	1,946.3	431.6	556.4	987.9															-9.0%	22.2%	6.3%
Regular depreciation and amortization*	207.1	186.0	393.0	192.4	585.4	232.6	425.0	818.0	211.9	219.5	431.4															2.3%	18.0%	9.7%
Amortization of purchased intangible assets	266.9	269.5	536.4	263.5	799.9	319.4	582.9	1,119.2	217.8	225.2	443.0															-18.4%	-16.5%	-17.4%
Impairments**	0.0	0.0	0.0	8.4	8.4	0.7	9.1	9.1	1.9	111.7	113.6															>1.000%	n.m.	>1.000%
<b>Total</b>	<b>852.8</b>	<b>1,073.9</b>	<b>1,926.7</b>	<b>1,072.3</b>	<b>2,999.0</b>	<b>1,067.3</b>	<b>2,139.6</b>	<b>4,066.3</b>	<b>1,147.5</b>	<b>1,047.5</b>	<b>2,195.1</b>															34.5%	-2.5%	13.9%
<b>Adjustments</b>																												
Acquisition costs	0.2	0.2	0.4	0.1	0.4	83.4	83.4	83.8	19.0	-29.5	-10.5															>1.000%	n.m.	n.m.
Restructuring costs	61.3	39.1	100.4	10.5	110.8	9.6	20.0	120.4	15.4	21.1	36.5															-74.8%	-45.9%	-63.6%
Integration costs/IT costs	13.0	22.0	35.0	27.8	62.8	32.4	60.2	95.2	21.7	37.0	58.8															67.0%	68.3%	67.8%
Gain (-)/ losses (+) on the divestment of businesse	1.8	-1.7	0.1	-3.7	-3.6	9.5	5.8	5.9	-30.0	2.1	-27.8															n.m.	n.m.	n.m.
Other one-time costs	-0.6	5.9	5.3	4.4	9.6	3.5	7.9	13.2	7.6	-4.0	3.5															n.m.	n.m.	-32.8%
<b>Total</b>	<b>75.7</b>	<b>65.4</b>	<b>141.1</b>	<b>39.0</b>	<b>180.1</b>	<b>138.4</b>	<b>177.3</b>	<b>318.5</b>	<b>33.8</b>	<b>26.7</b>	<b>60.5</b>															-55.3%	-59.2%	-57.1%
<b>EBITDA pre</b>	<b>928.5</b>	<b>1,139.3</b>	<b>2,067.8</b>	<b>1,111.3</b>	<b>3,179.1</b>	<b>1,205.7</b>	<b>2,316.9</b>	<b>4,384.8</b>	<b>1,181.3</b>	<b>1,074.2</b>	<b>2,255.5</b>															27.2%	-5.7%	9.1%

**b) Reconciliation to EPS pre**
**1) Reconciliation starting from EBITDA pre**

EBITDA pre	928.5	1,139.3	2,067.8	1,111.3	3,179.1	1,205.7	2,316.9	4,384.8	1,181.3	1,074.2	2,255.5															27.2%	-5.7%	9.1%
Regular depreciation and amortization*	-207.1	-186.0	-393.0	-192.4	-585.4	-232.6	-425.0	-818.0	-211.9	-219.5	-431.4															2.3%	18.0%	9.7%
Financial result	-112.6	-61.1	-173.7	-134.9	-308.5	-76.1	-210.9	-384.6	-98.5	-102.3	-200.7															-12.5%	67.4%	15.6%
Adjustments within Financial result	45.1	0.0	45.1	0.0	45.1	0.0	0.0	45.1	0.0	0.0	0.0																	
Profit before income tax pre	653.9	892.3	1,546.2	784.0	2,330.2	897.0	1,681.0	3,227.2	870.9	752.5	1,623.5															33.2%	-15.7%	5.0%
Income tax pre	-163.5	-223.1	-386.5	-196.0	-582.6	-224.2	-420.3	-806.8	-217.7	-188.1	-405.9															33.2%	-15.7%	5.0%
underlying tax rate	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%																	
Non-controlling interest	-1.0	0.0	-1.0	0.8	-0.1	-3.2	-2.4	-3.3	-1.9	0.8	-1.1															99.8%	n.m.	14.9%
Net income pre	489.5	669.2	1,158.7	588.8	1,747.5	669.5	1,258.4	2,417.1	651.3	565.2	1,216.5															33.1%	-15.5%	5.0%
<b>EPS pre in €***</b>	<b>1.13</b>	<b>1.54</b>	<b>2.67</b>	<b>1.35</b>	<b>4.02</b>	<b>1.54</b>	<b>2.89</b>	<b>5.56</b>	<b>1.50</b>	<b>1.30</b>	<b>2.80</b>															33.1%	-15.5%	5.0%

**2) Reconciliation starting from Profit before tax**

Profit before income tax	266.2	557.4	823.6	473.2	1,296.8	438.6	911.8	1,735.4	617.5	388.9	1,006.4															131.9%	-30.2%	22.2%
Amortization of purchased intangible assets	266.9	269.5	536.4	263.5	799.9	319.4	582.9	1,119.2	217.8	225.2	443.0															-18.4%	-16.5%	-17.4%
Impairments**	0.0	0.0	0.0	8.4	8.4	0.7	9.1	9.1	1.9	111.7	113.6															>1.000%	n.m.	>1.000%
<b>Adjustments</b>																												
Acquisition costs	0.2	0.2	0.4	0.1	0.4	83.4	83.4	83.8	19.0	-29.5	-10.5															>1.000%	n.m.	n.m.
Restructuring costs	61.3	39.1	100.4	10.5	110.8	9.6	20.0	120.4	15.4	21.1	36.5															-74.8%	-45.9%	-63.6%
Integration costs/IT costs	13.0	22.0	35.0	27.8	62.8	32.4	60.2	95.2	21.7	37.0	58.8															67.0%	68.3%	67.8%
Gain (-)/ losses (+) on the divestment of businesse	1.8	-1.7	0.1	-3.7	-3.6	9.5	5.8	5.9	-30.0	2.1	-27.8															n.m.	n.m.	n.m.
Other one-time costs	-0.6	5.9	5.3	4.4	9.6	3.5	7.9	13.2	7.6	-4.0	3.5															n.m.	n.m.	-32.8%
Adjustments within Financial result	45.1	0.0	45.1	0.0	45.1	0.0	0.0	45.1	0.0	0.0	0.0																	
Total adjustments	120.7	65.4	186.2	39.0	225.1	138.4	177.3	363.5	33.8	26.7	60.5															-72.0%	-59.2%	-67.5%
Profit before income tax pre	653.9	892.3	1,546.2	784.0	2,330.2	897.0	1,681.0	3,227.2	870.9	752.5	1,623.5															33.2%	-15.7%	5.0%
Income tax pre	-163.5	-223.1	-386.5	-196.0	-582.6	-224.2	-420.3	-806.8	-217.7	-188.1	-405.9															33.2%	-15.7%	5.0%
underlying tax rate	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%																	
<b>Total costs excluded from Net income</b>	<b>300.9</b>	<b>198.3</b>	<b>499.2</b>	<b>246.1</b>	<b>745.4</b>	<b>351.5</b>	<b>597.6</b>	<b>1,096.8</b>	<b>195.2</b>	<b>275.4</b>	<b>470.5</b>															-35.1%	38.8%	-5.7%
Total costs excluded from EPS in €	0.69	0.46	1.15	0.57	1.71	0.81	1.37	2.52	0.45	0.63	1.08															-34.8%	37.0%	-6.1%
Non-controlling interest	-1.0	0.0	-1.0	0.8	-0.1	-3.2	-2.4	-3.3	-1.9	0.8	-1.1															99.8%	n.m.	14.9%
Net income pre	489.5	669.2	1,158.7	588.8	1,747.5	669.5	1,258.4	2,417.1	651.3	565.2	1,216.5															33.1%	-15.5%	5.0%
<b>EPS pre in €***</b>	<b>1.13</b>	<b>1.54</b>	<b>2.67</b>	<b>1.35</b>	<b>4.02</b>	<b>1.54</b>	<b>2.89</b>	<b>5.56</b>	<b>1.50</b>	<b>1.30</b>	<b>2.80</b>															32.7%	-15.6%	4.9%

Number of theoretical shares in million 434.8 434.8 434.8 434.8 434.8 434.8 434.8 434.8 434.8 434.8 434.8

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

\*\* only reflects impairments which classified as adjustments

\*\*\* for continuing operations

Sum of items may not foot due to rounding.





**Detailed reconciliation - Healthcare**

€ million	2019								2020								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>EBIT</b>	<b>127.8</b>	<b>345.1</b>	<b>472.9</b>	<b>325.4</b>	<b>798.2</b>	<b>351.2</b>	<b>676.6</b>	<b>1,149.5</b>	<b>422.3</b>	<b>269.2</b>	<b>691.5</b>						230.5%	-22.0%	46.2%					
Regular depreciation and amortization*	88.0	64.1	152.0	65.0	217.0	76.1	141.1	293.1	66.8	73.7	140.5						-24.0%	15.1%	-7.6%					
Amortization of purchased intangible assets	113.3	113.4	226.7	113.2	339.8	112.9	226.0	452.7	10.1	16.0	26.1						-91.1%	-85.9%	-88.5%					
Impairments**	0.0	0.0	0.0	0.0	0.0	1.1	1.1	1.1	1.9	0.0	1.9						n.m.	n.m.	n.m.					
<b>Total depreciation and amortization</b>	<b>201.3</b>	<b>177.4</b>	<b>378.7</b>	<b>178.2</b>	<b>556.9</b>	<b>190.0</b>	<b>368.2</b>	<b>746.9</b>	<b>78.8</b>	<b>89.7</b>	<b>168.5</b>						-60.9%	-49.4%	-55.5%					
<b>EBITDA</b>	<b>329.1</b>	<b>522.5</b>	<b>851.6</b>	<b>503.5</b>	<b>1,355.1</b>	<b>541.2</b>	<b>1,044.8</b>	<b>1,896.4</b>	<b>501.0</b>	<b>359.0</b>	<b>860.0</b>						52.3%	-31.3%	1.0%					
<b>Adjustments</b>																								
<b>Acquisition costs</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>						n.m.	n.m.	n.m.					
<b>Restructuring costs</b>																								
Restructuring costs	0.1	4.7	4.8	1.5	6.3	10.7	12.2	17.0	2.0	12.4	14.4						>1.000%	166.0%	199.5%					
<b>Total</b>	<b>0.1</b>	<b>4.7</b>	<b>4.8</b>	<b>1.5</b>	<b>6.3</b>	<b>10.7</b>	<b>12.2</b>	<b>17.0</b>	<b>2.0</b>	<b>12.4</b>	<b>14.4</b>						>1.000%	166.0%	199.5%					
<b>Integration costs/IT costs</b>																								
Integration Cost	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0						n.m.	n.m.	n.m.					
ERP/HR systems	1.9	3.6	5.4	2.1	7.5	5.3	7.4	12.8	0.9	1.3	2.2						-50.9%	-63.7%	-59.3%					
<b>Total</b>	<b>1.9</b>	<b>3.6</b>	<b>5.4</b>	<b>2.1</b>	<b>7.5</b>	<b>5.3</b>	<b>7.4</b>	<b>12.8</b>	<b>0.9</b>	<b>1.3</b>	<b>2.2</b>						-50.9%	-63.7%	-59.3%					
<b>Gain (-)/ losses (+) on the divestment of businesses</b>																								
Sale of Kuvan and Biosimilars	0.0	-4.9	-4.8	0.0	-4.8	1.0	1.0	-3.8	0.1	-1.7	-1.7						43.5%	-64.8%	-65.8%					
Sale of Consumer Health	0.8	1.9	2.7	-6.4	-3.7	2.9	-3.5	-0.8	4.6	3.0	7.7						494.6%	57.1%	183.7%					
Sale of Allergopharma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-36.5	-0.1	36.5						n.m.							
Others	0.0	0.0	0.0	0.0	0.0	-0.1	-0.1	-0.1	0.0	0.0	0.0						n.m.							
<b>Total</b>	<b>0.8</b>	<b>-3.0</b>	<b>-2.1</b>	<b>-6.4</b>	<b>-8.5</b>	<b>4.0</b>	<b>-2.4</b>	<b>-4.5</b>	<b>-31.8</b>	<b>1.4</b>	<b>-30.4</b>						n.m.	n.m.	>1.000%					
<b>Other one-time costs</b>																								
Others	0.1	0.1	0.1	0.0	0.1	-0.1	-0.1	0.0	0.0	0.0	0.0						-100.0%	-100.0%	-100.0%					
<b>Total</b>	<b>0.1</b>	<b>0.1</b>	<b>0.1</b>	<b>0.0</b>	<b>0.1</b>	<b>-0.1</b>	<b>-0.1</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>						-100.0%	-100.0%	-100.0%					
<b>Total adjustments</b>	<b>2.9</b>	<b>5.3</b>	<b>8.2</b>	<b>-2.8</b>	<b>5.5</b>	<b>19.9</b>	<b>17.1</b>	<b>25.4</b>	<b>-28.9</b>	<b>15.1</b>	<b>-13.8</b>						n.m.	183.3%	n.m.					
<b>EBITDA pre</b>	<b>332.0</b>	<b>527.8</b>	<b>859.8</b>	<b>500.8</b>	<b>1,360.6</b>	<b>561.1</b>	<b>1,061.9</b>	<b>1,921.7</b>	<b>472.1</b>	<b>374.0</b>	<b>846.2</b>						42.2%	-29.1%	-1.6%					

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

\*\* only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.

**Income Statement Merck KGaA, Darmstadt, Germany**
**Life Science**

€ million

	2019								2020							Change YoY										
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY		
<b>Net sales</b>	<b>1,661.0</b>	<b>1,705.5</b>	<b>3,366.5</b>	<b>1,715.2</b>	<b>5,081.7</b>	<b>1,782.6</b>	<b>3,497.9</b>	<b>6,864.3</b>	<b>1,768.9</b>	<b>1,806.2</b>	<b>3,575.1</b>						6.5%	5.9%	6.2%							
Cost of sales	-719.0	-723.9	-1,442.9	-747.8	-2,190.7	-770.8	-1,518.6	-2,961.5	-744.5	-773.7	-1,518.2						3.5%	6.9%	5.2%							
thereof amortization of intangible assets	-14.4	-14.5	-28.9	-14.6	-43.5	-15.0	-29.6	-58.5	-15.0	-15.4	-30.3						3.7%	6.0%	4.9%							
Gross profit	942.0	981.6	1,923.6	967.4	2,891.0	1,011.8	1,979.2	3,902.8	1,024.4	1,032.5	2,056.9						8.8%	5.2%	6.9%							
<i>in % of net sales</i>	56.7%	57.6%	57.1%	56.4%	56.9%	56.8%	56.6%	56.9%	57.9%	57.2%	57.5%															
SG&A	-566.8	-590.5	-1,157.3	-584.2	-1,741.4	-604.7	-1,188.9	-2,346.2	-603.8	-571.6	-1,175.4						6.5%	-3.2%	1.6%							
<i>in % of net sales</i>	34.1%	34.6%	34.4%	34.1%	34.3%	33.9%	34.0%	34.2%	34.1%	31.6%	32.9%															
Marketing and selling expenses	-469.5	-489.8	-959.3	-474.4	-1,433.7	-489.9	-964.3	-1,923.6	-497.5	-488.1	-985.6						6.0%	-0.3%	2.7%							
thereof amortization of intangible assets (M&S)	-107.6	-109.3	-216.9	-103.4	-320.3	-103.2	-206.6	-423.5	-104.0	-104.1	-208.1						-3.4%	-4.7%	-4.1%							
Administration expenses	-87.5	-68.4	-155.9	-83.2	-239.1	-101.9	-185.1	-341.1	-89.2	-100.3	-189.5						1.9%	46.6%	21.5%							
Impairment losses and reversals (IFRS 9)	0.0	-0.3	-0.3	-2.6	-2.9	-3.8	-6.4	-6.7	0.4	-0.9	-0.4						>1.000%	187.5%	47.9%							
Other operating expenses/income	-9.8	-32.0	-41.8	-23.9	-65.7	-9.1	-33.1	-74.8	-17.6	17.7	0.1						80.1%	n.m.	n.m.							
Impairments**	0.0	0.0	0.0	-0.1	-0.1	0.0	-0.1	-0.1	0.0	0.0	0.0						-100.0%	-100.0%	-100.0%							
Research and development	-61.8	-69.4	-131.2	-67.3	-198.5	-77.7	-145.0	-276.2	-75.3	-75.4	-150.7						21.9%	8.6%	14.8%							
<i>in % of net sales</i>	3.7%	4.1%	3.9%	3.9%	3.9%	4.4%	4.1%	4.0%	4.3%	4.2%	4.2%															
thereof amortization of intangible assets (R&D)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0						135.8%	n.m.	1.8%							
<b>EBIT</b>	<b>313.4</b>	<b>321.7</b>	<b>635.1</b>	<b>316.0</b>	<b>951.1</b>	<b>329.3</b>	<b>645.3</b>	<b>1,280.4</b>	<b>345.3</b>	<b>385.6</b>	<b>730.9</b>						10.2%	19.9%	15.1%							
<i>in % of net sales</i>	18.9%	18.9%	18.9%	18.4%	18.7%	18.5%	18.4%	18.7%	19.5%	21.3%	20.4%															
Depreciation and amortization	193.5	196.6	390.1	194.9	584.9	204.4	399.2	789.3	196.0	198.8	394.8						1.3%	1.1%	1.2%							
<b>EBITDA</b>	<b>506.8</b>	<b>518.3</b>	<b>1,025.1</b>	<b>510.9</b>	<b>1,536.0</b>	<b>533.7</b>	<b>1,044.6</b>	<b>2,069.7</b>	<b>541.3</b>	<b>584.4</b>	<b>1,125.7</b>						6.8%	12.8%	9.8%							
<i>in % of net sales</i>	30.5%	30.4%	30.5%	29.8%	30.2%	29.9%	29.9%	30.2%	30.6%	32.4%	31.5%															
<b>EBITDA pre</b>	<b>515.7</b>	<b>533.3</b>	<b>1,049.0</b>	<b>531.1</b>	<b>1,580.1</b>	<b>548.7</b>	<b>1,079.8</b>	<b>2,128.9</b>	<b>552.7</b>	<b>569.0</b>	<b>1,121.8</b>						7.2%	6.7%	6.9%							
<i>in % of net sales</i>	31.0%	31.3%	31.2%	31.0%	31.1%	30.8%	30.9%	31.0%	31.2%	31.5%	31.4%															
<b>Reconciliation to EBITDA pre</b>																										
EBITDA	506.8	518.3	1,025.1	510.9	1,536.0	533.7	1,044.6	2,069.7	541.3	584.4	1,125.7						6.8%	12.8%	9.8%							
<b>Adjustments</b>																										
thereof: Cost of Sales	0.7	0.5	1.2	2.3	3.4	1.6	3.8	5.0	0.2	0.0	0.3						-65.8%	-90.9%	-76.1%							
thereof: Marketing and selling expenses	0.5	0.1	0.7	0.9	1.6	0.0	0.9	1.5	0.1	0.0	0.1						-85.7%	n.m.	-89.8%							
thereof: Administration expenses	6.1	-0.6	5.5	6.0	11.6	22.1	28.2	33.7	9.3	12.1	21.5						52.0%	n.m.	286.9%							
thereof: Other operating expenses/income	1.4	14.9	16.3	11.1	27.4	-8.7	2.4	18.8	1.8	-27.5	-25.8						28.7%	n.m.	n.m.							
thereof: Research and development	0.2	0.0	0.2	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0						-100.0%	-100.0%	-100.0%							
<b>Total</b>	<b>8.9</b>	<b>15.0</b>	<b>23.9</b>	<b>20.3</b>	<b>44.1</b>	<b>15.0</b>	<b>35.3</b>	<b>59.1</b>	<b>11.4</b>	<b>-15.4</b>	<b>-4.0</b>						27.5%	n.m.	n.m.							
<b>EBITDA pre</b>	<b>515.7</b>	<b>533.3</b>	<b>1,049.0</b>	<b>531.1</b>	<b>1,580.1</b>	<b>548.7</b>	<b>1,079.8</b>	<b>2,128.9</b>	<b>552.7</b>	<b>569.0</b>	<b>1,121.8</b>						7.2%	6.7%	6.9%							

Sum of items may not foot due to rounding.



**Income Statement Merck KGaA, Darmstadt, Germany**
**Performance Materials**

€ million

	2019								2020								Change YoY									
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY		
<b>Net sales</b>	<b>604.1</b>	<b>589.0</b>	<b>1,193.1</b>	<b>582.7</b>	<b>1,775.8</b>	<b>797.9</b>	<b>1,380.5</b>	<b>2,573.6</b>	<b>900.3</b>	<b>813.6</b>	<b>1,713.9</b>						49.0%	38.1%	43.7%							
Cost of sales	-337.9	-306.9	-644.8	-314.7	-959.5	-477.2	-792.0	-1,436.8	-515.1	-472.0	-987.1						52.4%	53.8%	53.1%							
thereof amortization of intangible assets	-28.2	-28.2	-56.4	-28.5	-84.9	-41.0	-69.5	-125.9	-41.0	-41.0	-82.0						45.3%	45.6%	45.5%							
Gross profit	266.3	282.0	548.3	267.9	816.2	320.6	588.6	1,136.9	385.3	341.6	726.8						44.7%	21.1%	32.6%							
<i>in % of net sales</i>	44.1%	47.9%	46.0%	46.0%	46.0%	40.2%	42.6%	44.2%	42.8%	42.0%	42.4%															
SG&A	-99.3	-108.1	-207.4	-121.8	-329.2	-233.3	-355.1	-562.6	-197.6	-303.4	-501.0						99.0%	180.6%	141.6%							
<i>in % of net sales</i>	16.4%	18.4%	17.4%	20.9%	18.5%	29.2%	25.7%	21.9%	21.9%	37.3%	29.2%															
Marketing and selling expenses	-65.9	-66.1	-132.0	-61.0	-193.0	-136.0	-197.0	-329.0	-135.6	-133.9	-269.5						105.8%	102.6%	104.2%							
thereof amortization of intangible assets (M&S)	-2.8	-3.7	-6.4	-3.4	-9.8	-46.8	-50.2	-56.6	-47.3	-47.4	-94.7						>1.000%	>1.000%	>1.000%							
Administration expenses	-23.4	-25.3	-48.7	-29.6	-78.3	-39.3	-69.0	-117.7	-38.4	-44.4	-82.7						63.8%	75.5%	69.9%							
Impairment losses and reversals (IFRS 9)	-0.1	-0.1	-0.1	0.5	0.4	0.1	0.6	0.5	0.6	-0.7	-0.1						n.m.	>1.000%	-19.6%							
Other operating expenses/income	-9.9	-16.7	-26.6	-31.6	-58.2	-58.2	-89.8	-116.4	-24.2	-124.4	-148.6						144.8%	645.8%	459.2%							
Impairments**	0.0	0.0	0.0	-8.3	-8.3	0.9	-7.4	-7.4	0.0	-111.6	-111.6						n.m.	n.m.	n.m.							
Research and development	-71.8	-74.4	-146.1	-48.1	-194.2	-73.0	-121.1	-267.2	-71.3	-68.3	-139.7						-0.6%	-8.1%	-4.4%							
<i>in % of net sales</i>	11.9%	12.6%	12.2%	8.3%	10.9%	9.2%	8.8%	10.4%	7.9%	8.4%	8.1%															
thereof amortization of intangible assets (R&D)	-0.6	-0.5	-1.1	-0.5	-1.5	-0.5	-1.0	-2.0	-0.5	-1.2	-1.7						-22.2%	159.9%	59.4%							
<b>EBIT</b>	<b>95.2</b>	<b>99.5</b>	<b>194.8</b>	<b>98.1</b>	<b>292.8</b>	<b>14.3</b>	<b>112.3</b>	<b>307.1</b>	<b>116.3</b>	<b>-30.2</b>	<b>86.1</b>						22.1%	n.m.	-55.8%							
<i>in % of net sales</i>	15.8%	16.9%	16.3%	16.8%	16.5%	1.8%	8.1%	11.9%	12.9%	-3.7%	5.0%															
Depreciation and amortization	61.9	61.7	123.6	71.3	194.9	135.1	206.4	330.0	134.7	249.2	383.9						117.5%	304.1%	210.6%							
<b>EBITDA</b>	<b>157.1</b>	<b>161.2</b>	<b>318.3</b>	<b>169.4</b>	<b>487.7</b>	<b>149.3</b>	<b>318.7</b>	<b>637.0</b>	<b>251.0</b>	<b>219.0</b>	<b>470.0</b>						59.7%	35.9%	47.6%							
<i>in % of net sales</i>	26.0%	27.4%	26.7%	29.1%	27.5%	18.7%	23.1%	24.8%	27.9%	26.9%	27.4%															
<b>EBITDA pre</b>	<b>192.6</b>	<b>190.3</b>	<b>382.9</b>	<b>177.5</b>	<b>560.4</b>	<b>243.0</b>	<b>420.5</b>	<b>803.4</b>	<b>285.5</b>	<b>238.3</b>	<b>523.8</b>						48.3%	25.2%	36.8%							
<i>in % of net sales</i>	31.9%	32.3%	32.1%	30.5%	31.6%	30.5%	30.5%	31.2%	31.7%	29.3%	30.6%															
<b>Reconciliation to EBITDA pre</b>																										
EBITDA	157.1	161.2	318.3	169.4	487.7	149.3	318.7	637.0	251.0	219.0	470.0						59.7%	35.9%	47.6%							
<b>Adjustments</b>																										
thereof: Cost of Sales	15.3	3.0	18.2	5.0	23.3	27.7	32.7	50.9	19.8	2.5	22.2						29.6%	-16.7%	22.0%							
thereof: Marketing and selling expenses	2.4	4.6	7.0	-1.4	5.6	0.4	-0.9	6.1	1.3	2.6	3.9						-46.5%	-42.3%	-43.8%							
thereof: Administration expenses	1.3	0.9	2.2	6.8	9.0	1.6	8.4	10.6	0.3	8.6	8.9						-75.7%	812.7%	301.2%							
thereof: Other operating expenses/income	0.9	3.6	4.5	8.1	12.7	59.7	67.8	72.3	14.4	5.9	20.3						>1.000%	63.0%	349.3%							
thereof: Research and development	15.5	17.0	32.6	-10.5	22.1	4.4	-6.2	26.4	-1.3	-0.3	-1.6						n.m.	n.m.	n.m.							
<b>Total</b>	<b>35.4</b>	<b>29.1</b>	<b>64.6</b>	<b>8.1</b>	<b>72.6</b>	<b>93.7</b>	<b>101.8</b>	<b>166.4</b>	<b>34.6</b>	<b>19.2</b>	<b>53.8</b>						-2.4%	-34.0%	-16.7%							
<b>EBITDA pre</b>	<b>192.6</b>	<b>190.3</b>	<b>382.9</b>	<b>177.5</b>	<b>560.4</b>	<b>243.0</b>	<b>420.5</b>	<b>803.4</b>	<b>285.5</b>	<b>238.3</b>	<b>523.8</b>						48.3%	25.2%	36.8%							

Sum of items may not foot due to rounding.

**Detailed reconciliation - Performance Materials**

€ million	2019								2020								Change YoY								
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	
<b>EBIT</b>	<b>95.2</b>	<b>99.5</b>	<b>194.8</b>	<b>98.1</b>	<b>292.8</b>	<b>14.3</b>	<b>112.3</b>	<b>307.1</b>	<b>116.3</b>	<b>-30.2</b>	<b>86.1</b>							22.1%	n.m.	-55.8%					
Regular depreciation and amortization*	30.4	29.4	59.7	30.7	90.4	47.6	78.3	138.0	45.9	47.9	93.8							51.2%	63.3%	57.2%					
Amortization of purchased intangible assets	31.5	32.3	63.9	32.3	96.2	88.3	120.6	184.5	88.8	89.7	178.4							181.4%	177.4%	179.4%					
Impairments**	0.0	0.0	0.0	8.3	8.3	-0.9	7.4	7.4	0.0	111.6	111.6							n.m.	n.m.	n.m.					
<b>Total depreciation and amortization</b>	<b>61.9</b>	<b>61.7</b>	<b>123.6</b>	<b>71.3</b>	<b>194.9</b>	<b>135.1</b>	<b>206.4</b>	<b>330.0</b>	<b>134.7</b>	<b>249.2</b>	<b>383.9</b>							117.5%	304.1%	210.6%					
<b>EBITDA</b>	<b>157.1</b>	<b>161.2</b>	<b>318.3</b>	<b>169.4</b>	<b>487.7</b>	<b>149.3</b>	<b>318.7</b>	<b>637.0</b>	<b>251.0</b>	<b>219.0</b>	<b>470.0</b>							59.7%	35.9%	47.6%					
<b>Adjustments</b>																									
<b>Acquisition costs</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>81.8</b>	<b>81.8</b>	<b>81.8</b>	<b>19.0</b>	<b>0.5</b>	<b>19.4</b>							n.m.	n.m.	n.m.					
<b>Restructuring costs</b>																									
Restructuring costs	34.1	26.3	60.5	0.9	61.3	-0.4	0.4	60.9	7.4	2.5	9.9							-78.4%	-90.6%	-83.7%					
<b>Total</b>	<b>34.1</b>	<b>26.3</b>	<b>60.5</b>	<b>0.9</b>	<b>61.3</b>	<b>-0.4</b>	<b>0.4</b>	<b>60.9</b>	<b>7.4</b>	<b>2.5</b>	<b>9.9</b>							-78.4%	-90.6%	-83.7%					
<b>Integration costs/IT costs</b>																									
Integration Cost	0.0	1.3	1.3	3.3	4.6	7.5	10.8	12.1	7.1	10.7	17.8							>1.000%	724.0%	>1.000%					
ERP/HR systems	1.3	1.5	2.8	3.9	6.7	4.7	8.6	11.4	1.1	5.6	6.6							-18.7%	269.8%	136.1%					
<b>Total</b>	<b>1.3</b>	<b>2.8</b>	<b>4.1</b>	<b>7.2</b>	<b>11.3</b>	<b>12.2</b>	<b>19.4</b>	<b>23.5</b>	<b>8.2</b>	<b>16.3</b>	<b>24.5</b>							525.0%	479.9%	494.2%					
<b>Gain (-)/ losses (+) on the divestment of businesses</b>																									
Costs related to former business activities	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.1	0.0	0.1							n.m.	n.m.	n.m.					
<b>Total</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.2</b>	<b>0.2</b>	<b>0.2</b>	<b>0.1</b>	<b>0.0</b>	<b>0.1</b>							n.m.	n.m.	n.m.					
<b>Other one-time costs</b>																									
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0							-100.0%	-100.0%	-100.0%					
<b>Total</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>							-100.0%	-100.0%	-100.0%					
<b>Total adjustments</b>	<b>35.4</b>	<b>29.1</b>	<b>64.6</b>	<b>8.1</b>	<b>72.6</b>	<b>93.7</b>	<b>101.8</b>	<b>166.4</b>	<b>34.6</b>	<b>19.2</b>	<b>53.8</b>							-2.4%	-34.0%	-16.7%					
<b>EBITDA pre</b>	<b>192.6</b>	<b>190.3</b>	<b>382.9</b>	<b>177.5</b>	<b>560.4</b>	<b>243.0</b>	<b>420.5</b>	<b>803.4</b>	<b>285.5</b>	<b>238.3</b>	<b>523.8</b>							48.3%	25.2%	36.8%					

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

\*\* only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.

**Income Statement Merck KGaA, Darmstadt, Germany**

Corporate/Others € million	2019								2020						Change YoY												
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY			
<b>Net sales</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>							n.m.	n.m.	n.m.							
Cost of sales	-1.8	-2.4	-4.1	2.5	-1.7	-1.1	1.4	-2.8	-0.6	-0.2	-0.8							-65.0%	-93.6%	-81.4%							
thereof amortization of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0							n.m.	n.m.	n.m.							
Gross profit	-1.8	-2.4	-4.1	2.5	-1.7	-1.1	1.4	-2.7	-0.6	-0.2	-0.8							-65.0%	-93.6%	-81.4%							
SG&A	-143.0	-130.7	-273.7	-119.6	-393.3	-161.8	-281.4	-555.1	-152.2	-122.8	-275.0							6.4%	-6.1%	0.5%							
Marketing and selling expenses	-5.0	-1.6	-6.6	-4.4	-11.0	-7.7	-12.1	-18.7	-2.2	-3.8	-6.0							-55.5%	133.5%	-9.4%							
thereof amortization of intangible assets (M&S)	-0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0							-99.7%	n.m.	2.8%							
Administration expenses	-84.6	-91.3	-175.8	-72.3	-248.1	-102.9	-175.2	-351.0	-81.6	-73.0	-154.6							-3.5%	-20.0%	-12.1%							
Impairment losses and reversals (IFRS 9)	-0.3	0.2	-0.1	0.2	0.1	-0.3	-0.1	-0.2	0.1	0.3	0.4							n.m.	74.1%	n.m.							
Other operating expenses/income	-53.2	-38.0	-91.2	-43.0	-134.2	-50.9	-94.0	-185.1	-68.5	-46.3	-114.8							28.8%	21.8%	25.9%							
Impairments**	0.0	0.0	0.0	0.0	0.0	-0.4	-0.4	-0.4	0.0	-0.2	-0.2							n.m.	n.m.	n.m.							
Research and development	-12.8	-14.8	-27.6	-14.3	-41.9	-17.3	-31.6	-59.2	-15.0	-10.6	-25.6							17.9%	-28.7%	-7.1%							
thereof amortization of intangible assets (R&D)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0							n.m.	n.m.	n.m.							
<b>EBIT</b>	<b>-157.5</b>	<b>-147.9</b>	<b>-305.4</b>	<b>-131.4</b>	<b>-436.8</b>	<b>-180.2</b>	<b>-311.5</b>	<b>-617.0</b>	<b>-167.9</b>	<b>-133.5</b>	<b>-301.4</b>							6.6%	-9.7%	-1.3%							
Depreciation and amortization	17.3	19.7	37.1	19.9	57.0	23.2	43.1	80.2	22.1	18.6	40.8							27.5%	-5.6%	9.9%							
<b>EBITDA</b>	<b>-140.2</b>	<b>-128.1</b>	<b>-268.3</b>	<b>-111.5</b>	<b>-379.8</b>	<b>-157.0</b>	<b>-268.5</b>	<b>-536.8</b>	<b>-145.8</b>	<b>-114.8</b>	<b>-260.6</b>							4.0%	-10.4%	-2.9%							
<b>EBITDA pre</b>	<b>-111.8</b>	<b>-112.1</b>	<b>-223.9</b>	<b>-98.1</b>	<b>-322.0</b>	<b>-147.2</b>	<b>-245.3</b>	<b>-469.2</b>	<b>-129.1</b>	<b>-107.2</b>	<b>-236.2</b>							15.5%	-4.5%	5.5%							
<b>Reconciliation to EBITDA pre</b>																											
EBITDA	-140.2	-128.1	-268.3	-111.5	-379.8	-157.0	-268.5	-536.8	-145.8	-114.8	-260.6							4.0%	-10.4%	-2.9%							
<b>Adjustments</b>																											
thereof: Cost of Sales	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0							n.m.	n.m.	n.m.							
thereof: Marketing and selling expenses	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0							n.m.	n.m.	n.m.							
thereof: Administration expenses	27.6	7.4	35.0	7.5	42.5	6.8	14.3	49.3	5.7	10.4	16.1							-79.2%	39.6%	-54.0%							
thereof: Other operating expenses/income	0.8	8.6	9.4	6.0	15.4	2.9	8.8	18.2	11.0	-2.7	8.3							>1.000%	n.m.	-11.6%							
thereof: Research and development	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0							n.m.	n.m.	n.m.							
<b>Total</b>	<b>28.4</b>	<b>16.0</b>	<b>44.4</b>	<b>13.4</b>	<b>57.8</b>	<b>9.8</b>	<b>23.2</b>	<b>67.6</b>	<b>16.7</b>	<b>7.7</b>	<b>24.4</b>							-41.2%	-51.9%	-45.0%							
<b>EBITDA pre</b>	<b>-111.8</b>	<b>-112.1</b>	<b>-223.9</b>	<b>-98.1</b>	<b>-322.0</b>	<b>-147.2</b>	<b>-245.3</b>	<b>-469.2</b>	<b>-129.1</b>	<b>-107.2</b>	<b>-236.2</b>							15.5%	-4.5%	5.5%							

Sum of items may not foot due to rounding.

**Detailed reconciliation - Corporate / Others**

€ million	2019								2020								Change YoY								
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	
<b>EBIT</b>	<b>-157.5</b>	<b>-147.9</b>	<b>-305.4</b>	<b>-131.4</b>	<b>-436.8</b>	<b>-180.2</b>	<b>-311.5</b>	<b>-617.0</b>	<b>-167.9</b>	<b>-133.5</b>	<b>-301.4</b>							6.6%	-9.7%	-1.3%					
Regular depreciation and amortization*	17.2	19.9	37.1	19.9	57.0	22.8	42.6	79.7	22.1	18.5	40.6							28.2%	-6.9%	9.4%					
Amortization of purchased intangible assets	0.1	-0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0							-99.7%	n.m.	2.8%					
Impairments**	0.0	0.0	0.0	0.0	0.0	0.4	0.4	0.4	0.0	0.2	0.2							n.m.	n.m.	n.m.					
<b>Total depreciation and amortization</b>	<b>17.3</b>	<b>19.8</b>	<b>37.1</b>	<b>19.9</b>	<b>57.0</b>	<b>23.2</b>	<b>43.1</b>	<b>80.2</b>	<b>22.1</b>	<b>18.6</b>	<b>40.8</b>							<b>27.5%</b>	<b>-5.6%</b>	<b>9.9%</b>					
<b>EBITDA</b>	<b>-140.2</b>	<b>-128.1</b>	<b>-268.3</b>	<b>-111.5</b>	<b>-379.8</b>	<b>-157.0</b>	<b>-268.5</b>	<b>-536.8</b>	<b>-145.8</b>	<b>-114.8</b>	<b>-260.6</b>							<b>4.0%</b>	<b>-10.4%</b>	<b>-2.9%</b>					
<b>Adjustments</b>																									
<b>Acquisition costs</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>							n.m.	n.m.	n.m.					
<b>Restructuring costs</b>																									
Restructuring costs	25.9	4.3	30.2	2.0	32.2	-2.2	-0.2	30.0	4.3	5.2	9.5							-83.4%	20.9%	-68.5%					
<b>Total</b>	<b>25.9</b>	<b>4.3</b>	<b>30.2</b>	<b>2.0</b>	<b>32.2</b>	<b>-2.2</b>	<b>-0.2</b>	<b>30.0</b>	<b>4.3</b>	<b>5.2</b>	<b>9.5</b>							<b>-83.4%</b>	<b>20.9%</b>	<b>-68.5%</b>					
<b>IT project costs</b>																									
Integration Cost	0.0	0.1	0.1	0.1	0.2	0.0	0.1	0.2	0.0	0.0	0.0														
ERP/HR systems	3.2	5.8	9.0	6.4	15.4	7.6	14.0	23.0	2.9	5.9	8.9							-8.1%	2.1%	-1.5%					
<b>Total</b>	<b>3.2</b>	<b>5.9</b>	<b>9.1</b>	<b>6.5</b>	<b>15.6</b>	<b>7.6</b>	<b>14.1</b>	<b>23.2</b>	<b>3.0</b>	<b>5.9</b>	<b>8.9</b>							<b>-6.7%</b>	<b>-0.5%</b>	<b>-2.7%</b>					
<b>Gain (-)/ losses (+) on the divestment of businesses</b>																									
Costs related to former business activities	0.0	0.0	0.0	0.5	0.5	0.8	1.3	1.3	1.8	0.7	2.5							>1.000%	n.m.	n.m.					
<b>Total</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.5</b>	<b>0.5</b>	<b>0.8</b>	<b>1.3</b>	<b>1.3</b>	<b>1.8</b>	<b>0.7</b>	<b>2.5</b>							<b>&gt;1.000%</b>	<b>n.m.</b>	<b>n.m.</b>					
<b>Other one-time costs</b>																									
Others	-0.7	5.8	5.1	4.4	9.5	3.6	8.0	13.1	7.6	-4.0	3.5							n.m.	n.m.	-30.9%					
<b>Total</b>	<b>-0.7</b>	<b>5.8</b>	<b>5.1</b>	<b>4.4</b>	<b>9.5</b>	<b>3.6</b>	<b>8.0</b>	<b>13.1</b>	<b>7.6</b>	<b>-4.0</b>	<b>3.5</b>							<b>n.m.</b>	<b>n.m.</b>	<b>-30.9%</b>					
<b>Total adjustments</b>	<b>28.4</b>	<b>16.0</b>	<b>44.4</b>	<b>13.4</b>	<b>57.8</b>	<b>9.8</b>	<b>23.2</b>	<b>67.6</b>	<b>16.7</b>	<b>7.7</b>	<b>24.4</b>							<b>-41.2%</b>	<b>-51.9%</b>	<b>-45.0%</b>					
<b>EBITDA pre</b>	<b>-111.8</b>	<b>-112.1</b>	<b>-223.9</b>	<b>-98.1</b>	<b>-322.0</b>	<b>-147.2</b>	<b>-245.3</b>	<b>-469.2</b>	<b>-129.1</b>	<b>-107.2</b>	<b>-236.2</b>							<b>15.5%</b>	<b>-4.5%</b>	<b>5.5%</b>					

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

\*\* only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.

**Cash Flow Statement Merck KGaA, Darmstadt, Germany**
**Group**

€ million

	2019							2020					Change YoY												
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	
<b>Profit after tax</b>	189.5	470.9	660.4	341.9	1,002.3	321.3	663.2	1,323.6	458.0	289.0	747.1						141.7%	-38.6%	13.1%						
Depreciation/amortization/impairment losses/write-ups	474.0	453.0	927.0	464.2	1,391.3	552.4	1,016.6	1,943.6	431.5	559.3	990.7						-9.0%	23.4%	6.9%						
of tangible assets	161.7	167.2	328.9	181.6	510.4	208.0	389.6	718.5	189.3	208.0	397.3						17.1%	24.4%	20.8%						
of intangible assets	312.3	288.3	600.6	282.7	883.3	344.6	627.3	1,227.9	242.3	348.3	596.6						-22.4%	20.8%	-1.7%						
of financial assets	0.0	-2.4	-2.4	-0.1	-2.5	-0.3	-0.3	-2.7	-0.1	2.9	2.8						n.m.	n.m.	n.m.						
Changes in working capital	-178.2	-58.3	-236.4	-93.9	-330.3	160.8	66.9	-169.5	-355.8	-112.4	-468.3						99.7%	93.0%	98.1%						
Changes in inventories	-145.7	-113.2	-258.9	-57.4	-316.4	-7.1	-64.6	-323.5	-128.7	-117.9	-246.6						-11.7%	4.2%	-4.8%						
Changes in trade accounts receivable	-14.9	-103.9	-118.8	-23.1	-141.9	95.2	72.1	-46.8	-254.3	74.7	-179.6						>1,000%	n.m.	51.2%						
Changes in trade accounts payable	-17.5	158.8	141.3	-13.3	128.0	72.8	59.5	200.8	27.1	-69.2	-42.0						n.m.	n.m.	n.m.						
Changes in provisions	100.2	-46.6	53.6	80.6	134.2	19.0	99.6	153.2	15.8	-53.8	-38.0						-84.2%	15.4%	n.m.						
Changes in other assets and liabilities	-89.1	-25.8	-114.9	128.8	13.9	-404.6	-275.8	-390.7	-22.9	-168.5	-189.3						-74.3%	544.7%	64.8%						
Neutralization of gain/loss on disposal of assets	1.0	-50.3	-49.3	10.0	-39.3	-17.9	-8.0	-57.3	-34.6	-3.9	-38.4						n.m.	-92.3%	-22.0%						
Other non-cash income and expenses	-5.0	-0.2	-5.3	-1.0	-6.3	59.5	58.5	53.2	24.4	-9.5	14.9						n.m.	>1,000%	n.m.						
<b>Net cash flows from operating activities</b>	<b>492.5</b>	<b>742.6</b>	<b>1,235.1</b>	<b>930.6</b>	<b>2,165.8</b>	<b>690.4</b>	<b>1,621.0</b>	<b>2,856.2</b>	<b>516.5</b>	<b>502.2</b>	<b>1,018.7</b>						<b>4.9%</b>	<b>-32.4%</b>	<b>-17.5%</b>						
thereof: from discontinued operations	0.0	-11.6	-11.6	11.6	0.0	0.0	11.6	0.0	0.0	0.0	0.0						n.m.	-100.0%	-100.0%						
Purchase of intangible assets	-9.2	-83.4	-92.6	-29.3	-121.8	-86.4	-115.6	-208.2	-17.9	-48.4	-66.3						95.0%	-41.9%	-28.4%						
Disposal of intangible assets	17.2	-0.3	16.9	7.6	24.5	-1.6	6.0	22.9	6.0	7.1	13.1						-64.9%	n.m.	-22.3%						
Purchase of property, plant and equipment	-208.7	-165.0	-373.8	-192.7	-566.5	-246.4	-439.1	-812.9	-340.8	-200.4	-541.2						63.3%	21.4%	44.8%						
Disposal of property, plant and equipment	2.9	3.5	6.4	-1.1	5.3	25.4	24.3	30.7	3.5	6.1	9.5						20.0%	73.6%	49.3%						
Acquisitions	-0.5	-9.7	-10.2	-56.4	-66.6	-4,960.1	-5,009.1	-5,019.8	-0.8	-5.8	-6.5						50.2%	-40.8%	-36.3%						
Divestments	-1.4	-90.6	-92.1	-5.7	-97.8	-12.4	-18.2	-110.2	56.1	-0.3	55.8						n.m.	-99.7%	n.m.						
Changes/ Purchase of financial assets	-37.0	-127.4	-164.4	-4.0	-168.5	-21.0	-32.4	-196.3	-25.6	-12.4	-38.0						-30.8%	-90.2%	-76.9%						
Disposal of financial assets	7.7	2.8	10.4	72.4	82.8	56.7	129.0	139.5	31.3	38.4	69.7						309.2%	>1,000%	569.5%						
Payments for investments in non-financial assets	-100.0	-399.9	-499.9	0.0	-499.9	0.0	0.0	-499.9	0.0	0.0	0.0						-100.0%	-100.0%	-100.0%						
Disposal of non-financial non-operative assets	0.0	0.0	0.0	0.0	0.0	501.5	501.5	501.5	0.0	0.0	0.0						n.m.	n.m.	n.m.						
<b>Net cash flows from investing activities</b>	<b>-329.1</b>	<b>-870.1</b>	<b>-1,199.2</b>	<b>-209.2</b>	<b>-1,408.4</b>	<b>-4,744.4</b>	<b>-4,953.6</b>	<b>-6,152.8</b>	<b>-288.1</b>	<b>-215.8</b>	<b>-503.9</b>						<b>-12.4%</b>	<b>-75.2%</b>	<b>-58.0%</b>						
thereof: from discontinued operations	-4.8	-106.9	-111.7	-6.4	-118.1	-11.3	-17.7	-129.4	0.0	0.0	0.0						-100.0%	-100.0%	-100.0%						
Dividend payments to Merck KGaA shareholders	0.0	-161.6	-161.6	0.0	-161.6	0.0	0.0	-161.6	0.0	-168.0	-168.0						n.m.	4.0%	4.0%						
Dividend payments to non-controlling interests	0.0	-11.4	-11.4	-0.2	-11.5	-0.1	-0.3	-11.7	-5.1	-0.2	-5.3						n.m.	-98.0%	-53.1%						
Profit transferred to E.Merck	-61.5	-453.9	-515.4	0.0	-515.4	0.0	0.0	-515.4	-57.6	-454.6	-512.2						-6.3%	0.1%	-0.6%						
Changes in financial liabilities to E.Merck	9.0	396.7	405.7	-193.8	212.0	-224.4	-418.2	-12.4	-34.1	389.6	355.5						n.m.	-1.8%	-12.4%						
Other changes in net equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0						n.m.	n.m.	-94.0%						
Changes in current and non-current financial liabilities	49.2	1,473.8	1,523.1	1,128.0	2,651.1	-48.2	1,079.8	2,602.9	638.2	-68.9	569.3						>1,000%	n.m.	-62.6%						
Other changes from financing activities	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.1						n.m.	n.m.	95.3%						
<b>Net cash flows from financing activities</b>	<b>-3.2</b>	<b>1,243.8</b>	<b>1,240.5</b>	<b>934.1</b>	<b>2,174.7</b>	<b>-272.7</b>	<b>661.4</b>	<b>1,901.9</b>	<b>541.5</b>	<b>-302.1</b>	<b>239.4</b>						<b>n.m.</b>	<b>n.m.</b>	<b>-80.7%</b>						
thereof: from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0						n.m.	n.m.	n.m.						
<b>Changes in cash and cash equivalents</b>	<b>160.2</b>	<b>1,116.3</b>	<b>1,276.5</b>	<b>1,655.5</b>	<b>2,932.0</b>	<b>-4,326.7</b>	<b>-2,671.2</b>	<b>-1,394.7</b>	<b>769.9</b>	<b>-15.7</b>	<b>754.2</b>						<b>380.6%</b>	<b>n.m.</b>	<b>-40.9%</b>						
Changes in cash and cash equivalents due to currency translation	9.4	-5.7	3.7	5.4	9.2	-4.1	1.3	5.0	-20.1	-2.7	-22.8						n.m.	-53.0%	n.m.						
Cash and cash equivalents as of January 1st	2,170.3	0.0	2,170.3	0.0	2,170.3	0.0	0.0	2,170.3	780.6	0.0	780.6						-64.0%	n.m.	-64.0%						
<b>Cash and cash equivalents</b>	<b>2,340.0</b>	<b>1,110.5</b>	<b>3,450.5</b>	<b>1,661.0</b>	<b>5,111.5</b>	<b>-4,330.9</b>	<b>-2,669.9</b>	<b>780.6</b>	<b>1,530.4</b>	<b>-18.4</b>	<b>1,512.0</b>						<b>-34.6%</b>	<b>n.m.</b>	<b>-56.2%</b>						
Changes in cash and cash equivalents due to change in scope of consolidation	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0						n.m.	n.m.	n.m.						
<b>Business Free Cash Flow</b>																									
<b>EBITDA pre</b>	<b>928.5</b>	<b>1,139.3</b>	<b>2,067.8</b>	<b>1,111.3</b>	<b>3,179.1</b>	<b>1,205.7</b>	<b>2,316.9</b>	<b>4,384.8</b>	<b>1,181.3</b>	<b>1,074.2</b>	<b>2,255.5</b>						<b>27.2%</b>	<b>-5.7%</b>	<b>9.1%</b>						
CAPEX on PPE and Software	-125.7	-193.2	-318.9	-209.6	-528.5	-497.9	-707.5	-1,026.4	-175.3	-220.9	-396.2						39.4%	14.3%	24.2%						
Changes in inventory	-172.9	-95.9	-268.8	-101.9	-370.6	-206.9	-308.7	-577.5	-101.3	-94.0	-195.3						-41.4%	-2.0%	-27.3%						
Changes in trade accounts receivable	-58.9	-116.1	-175.0	-33.6	-208.6	-50.8	-84.4	-259.4	-161.5	84.8	-76.7						174.3%	n.m.	-56.2%						
Leasing payments	-26.0	-33.1	-59.2	-34.8	-94.0	-41.8	-76.7	-135.8	-36.4	-31.2	-67.6						39.8%	-5.9%	14.2%						
Adjustments Business Free Cash Flow	0.0	0.0	0.0	0.0	0.0	345.6	345.6	345.6	-45.3	0.0	-45.3						n.m.	n.m.	n.m.						
<b>Business Free Cash Flow</b>	<b>545.0</b>	<b>701.0</b>	<b>1,246.0</b>	<b>731.4</b>	<b>1,977.5</b>	<b>753.8</b>	<b>1,485.3</b>	<b>2,731.3</b>	<b>661.5</b>	<b>812.9</b>	<b>1,474.4</b>						<b>21.4%</b>	<b>16.0%</b>	<b>18.3%</b>						
Healthcare	222.1	345.8	567.8	310.7	878.5	373.4	684.0	1,251.8	377.2	261.2	638.4						69.9%	-24.4%	12.4%						
Life Science	268.2	323.2	591.4	410.1	1,001.5	372.7	782.8	1,374.2	246.1	471.8	717.9						-8.2%	46.0%	21.4%						
Performance Materials	172.4	153.2	325.6	120.7	446.3	195.1	315.8	641.4	184.4	204.5	388.9						7.0%	33.5%	19.4%						
Corporate & Others	-117.6	-121.2	-238.8	-110.0	-348.8	-187.3	-297.3	-536.1	-146.2	-124.6	-270.7						24.3%	2.8%	13.4%						

**Balance Sheet Merck KGaA, Darmstadt, Germany**
**Group**

€ million

	2019				2020				Shares of Totals				Shares of Totals			
	31.mar	30.cze	30.wrz	31. Dez	31.mar	30.cze	30.wrz	31.gru	31.mar	30.cze	30.wrz	31. Dez	31.mar	30.cze	30.wrz	31.gru
<b>Current assets</b>	<b>10,512.5</b>	<b>11,693.9</b>	<b>13,517.6</b>	<b>9,003.3</b>	<b>10,012.8</b>	<b>9,726.2</b>			27.2%	29.6%	32.1%	20.6%	22.4%	22.2%		
Cash and cash equivalents	2,339.6	3,450.5	5,111.5	780.6	1,530.4	1,512.0			6.0%	8.7%	12.2%	1.8%	3.4%	3.5%		
Other current financial assets	64.5	153.7	275.5	57.1	81.0	32.0			0.2%	0.4%	0.7%	0.1%	0.2%	0.1%		
Trade and other current receivables	3,616.1	3,467.8	3,439.9	3,487.6	3,689.8	3,508.9			9.3%	8.8%	8.2%	8.0%	8.2%	8.0%		
Inventories	2,937.2	3,033.1	3,134.9	3,341.8	3,443.1	3,537.1			7.6%	7.7%	7.5%	7.6%	7.7%	8.1%		
Contract assets	42.4	71.6	68.5	156.1	84.7	92.5			0.1%	0.2%	0.2%	0.4%	0.2%	0.2%		
Other current non-financial assets	1,083.9	1,212.8	1,162.5	591.1	552.9	585.4			2.8%	3.1%	2.8%	1.3%	1.2%	1.3%		
Income tax receivables	428.9	304.5	324.7	589.1	630.9	458.2			1.1%	0.8%	0.8%	1.3%	1.4%	1.0%		
Assets held for sale	0.0	0.0	0.0	0.0	0.0	0.0			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%		
<b>Non-current assets</b>	<b>28,204.4</b>	<b>27,874.0</b>	<b>28,549.9</b>	<b>34,807.7</b>	<b>34,730.4</b>	<b>34,095.5</b>			72.8%	70.4%	67.9%	79.4%	77.6%	77.8%		
Goodwill	13,966.1	13,840.8	14,309.4	17,141.4	17,375.9	17,118.0			36.1%	35.0%	34.0%	39.1%	38.8%	39.1%		
Intangible assets other than goodwill	7,051.6	6,769.8	6,730.4	9,174.6	9,089.3	8,664.1			18.2%	17.1%	16.0%	20.9%	20.3%	19.8%		
Property, plant and equipment	5,290.8	5,250.7	5,376.3	6,213.3	6,110.4	6,067.3			13.7%	13.3%	12.8%	14.2%	13.7%	13.8%		
Investments at equity	0.0	0.0	0.0	0.0	0.0	0.0			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%		
Other non-current financial assets	595.1	656.7	641.1	738.3	692.0	673.5			1.5%	1.7%	1.5%	1.7%	1.5%	1.5%		
Other non-current receivables	14.1	13.3	14.3	22.3	21.4	20.6			0.0%	0.0%	0.0%	0.1%	0.0%	0.0%		
Other non-current non-financial assets	81.4	87.8	89.4	96.6	93.7	90.1			0.2%	0.2%	0.2%	0.2%	0.2%	0.2%		
Deferred tax assets	1,205.3	1,254.9	1,389.0	1,421.2	1,347.6	1,461.9			3.1%	3.2%	3.3%	3.2%	3.0%	3.3%		
<b>Total assets</b>	<b>38,716.8</b>	<b>39,567.9</b>	<b>42,067.4</b>	<b>43,811.0</b>	<b>44,743.2</b>	<b>43,821.7</b>			100.0%	100.0%	100.0%	100.0%	100.0%	100.0%		
<b>Current liabilities</b>	<b>11,194.4</b>	<b>10,494.3</b>	<b>9,655.1</b>	<b>11,841.6</b>	<b>10,764.3</b>	<b>10,079.8</b>			28.9%	26.5%	23.0%	27.0%	24.1%	23.0%		
Current financial debt	4,442.8	4,932.9	3,930.3	4,550.4	3,716.7	4,008.9			11.5%	12.5%	9.3%	10.4%	8.3%	9.1%		
Trade and other current payables	1,632.8	1,737.0	1,736.3	2,053.8	1,807.4	1,763.7			4.2%	4.4%	4.1%	4.7%	4.0%	4.0%		
Refund liabilities	541.3	564.8	587.4	564.6	626.1	596.8			1.4%	1.4%	1.4%	1.3%	1.4%	1.4%		
Other current financial liabilities	1,384.6	543.2	629.9	1,126.5	1,021.4	408.5			3.6%	1.4%	1.5%	2.6%	2.3%	0.9%		
Other current non-financial liabilities	1,322.9	1,064.8	1,099.5	1,211.2	1,225.5	1,121.8			3.4%	2.7%	2.6%	2.8%	2.7%	2.6%		
Income tax liabilities	1,279.4	1,106.7	1,126.4	1,401.9	1,463.0	1,319.3			3.3%	2.8%	2.7%	3.2%	3.3%	3.0%		
Current provisions	494.3	482.8	451.8	823.3	822.0	781.0			1.3%	1.2%	1.1%	1.9%	1.8%	1.8%		
Current employee benefit provisions	96.2	62.1	93.4	109.9	82.1	79.8			0.2%	0.2%	0.2%	0.3%	0.2%	0.2%		
Liabilities included in disposal groups classified as held for sale	0.0	0.0	0.0	0.0	0.0	0.0			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%		
<b>Non-current liabilities</b>	<b>9,846.7</b>	<b>11,499.4</b>	<b>14,230.1</b>	<b>14,055.6</b>	<b>15,378.6</b>	<b>15,716.0</b>			25.4%	29.1%	33.8%	32.1%	34.4%	35.9%		
Non-current financial debt	5,047.2	6,497.2	8,614.2	8,643.8	10,136.6	10,080.8			13.0%	16.4%	20.5%	19.7%	22.7%	23.0%		
Other non-current financial liabilities	36.5	34.2	32.8	43.4	44.1	53.8			0.1%	0.1%	0.1%	0.1%	0.1%	0.1%		
Other non-current non-financial liabilities	225.7	225.6	225.4	93.2	90.1	89.0			0.6%	0.6%	0.5%	0.2%	0.2%	0.2%		
Non-current provisions	630.1	632.4	656.4	253.7	252.3	254.6			1.6%	1.6%	1.6%	0.6%	0.6%	0.6%		
Non-current employee benefit provisions	2,688.8	2,947.4	3,518.1	3,193.5	3,060.5	3,524.6			6.9%	7.4%	8.4%	7.3%	6.8%	8.0%		
Deferred tax liabilities	1,218.3	1,162.5	1,183.2	1,828.0	1,795.1	1,713.2			3.1%	2.9%	2.8%	4.2%	4.0%	3.9%		
<b>Net equity</b>	<b>17,675.8</b>	<b>17,574.3</b>	<b>18,182.3</b>	<b>17,913.8</b>	<b>18,600.2</b>	<b>18,025.9</b>			45.7%	44.4%	43.2%	40.9%	41.6%	41.1%		
Equity capital	565.2	565.2	565.2	565.2	565.2	565.2			1.5%	1.4%	1.3%	1.3%	1.3%	1.3%		
Capital reserves	3,813.7	3,813.7	3,813.7	3,813.7	3,813.7	3,813.7			9.9%	9.6%	9.1%	8.7%	8.5%	8.7%		
Retained earnings	11,294.2	11,410.2	12,018.5	11,507.0	11,977.5	11,753.2			29.2%	28.8%	28.6%	26.3%	26.8%	26.8%		
Gain/losses recognized immediately in equity	1,967.3	1,761.0	1,761.0	1,979.6	2,199.9	1,850.0			5.1%	4.5%	4.2%	4.5%	4.9%	4.2%		
Non-controlling interest	35.4	24.1	23.8	48.3	43.9	43.8			0.1%	0.1%	0.1%	0.1%	0.1%	0.1%		
<b>Total liabilities and stockholders' equity</b>	<b>38,716.8</b>	<b>39,567.9</b>	<b>42,067.4</b>	<b>43,811.0</b>	<b>44,743.2</b>	<b>43,821.7</b>			100.0%	100.0%	100.0%	100.0%	100.0%	100.0%		

	2018				2019				Shares of Totals				Shares of Totals			
	31.mar	30.cze	30.wrz	31. Dez	31.mar	30.cze	30.wrz	31.gru	31.mar	30.cze	30.wrz	31. Dez	31.mar	30.cze	30.wrz	31.gru
Financial debt	9,490.0	11,430.1	12,544.5	13,194.2	13,853.3	14,089.7			24.5%	28.9%	29.8%	30.1%	31.0%	32.2%		
Net financial debt	7,089.4	7,829.4	7,320.0	12,363.2	12,284.6	12,560.2			18.3%	19.8%	17.4%	28.2%	27.5%	28.7%		

Income Statement Merck KGaA, Darmstadt, Germany

Group € million	2019								2020								Change YoY								
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	
<b>Financial result</b>	-112.6	-61.1	-173.7	-134.9	-308.5	-76.1	-210.9	-384.6	-98.5	-102.3	-200.7														
<b>Interest result</b>	-57.6	-55.5	-113.0	-85.4	-198.5	-93.8	-179.2	-292.3	-80.0	-72.8	-152.8							39.0%	31.3%	35.2%					
Interest income	6.7	22.0	28.6	6.9	35.6	30.1	37.1	65.7	5.6	10.9	16.5							-15.2%	-50.4%	-42.2%					
Interest expenses	-64.2	-77.5	-141.7	-92.4	-234.1	-123.9	-216.3	-358.0	-85.7	-83.7	-169.4							33.4%	8.1%	19.6%					
<b>Result from financial investments</b>	-0.4	-0.5	-0.9	0.2	-0.6	0.5	0.7	-0.1	-0.1	-0.8	-0.9							-66.8%	68.0%	9.4%					
<b>Currency difference - financing</b>	-37.7	2.3	-35.4	3.1	-32.3	-0.7	2.5	-33.0	-6.0	5.2	-0.8							-84.0%	129.8%	-97.8%					
<b>Interest quota - pensions and other provi</b>	-17.0	-6.8	-23.8	-52.8	-76.6	18.0	-34.8	-58.6	-12.3	-33.8	-46.2							-27.5%	397.3%	94.1%					
<b>Others</b>	0.0	-0.6	-0.6	0.0	-0.6	0.0	0.0	-0.6	0.0	0.0	0.0							n.m.	-100.0%	-100.0%					